Document is current
Any future updates will be listed below
-
Authors
Perner, Florian https://orcid.org/0000-0003-1010-3321
Pahl, Heike L.
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Heidel, Florian H. https://orcid.org/0000-0003-2438-1955
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (517204983)
- License Information
-
More Information
Article History
Received: 2 January 2025
Revised: 21 February 2025
Accepted: 13 March 2025
First Online: 26 March 2025
Competing interests
: FHH is a consultant for BMS/Celgene, AOP, Novartis, CTI, Janssen, AbbVie, GSK, Merck, CTI, Kartos, Telios and received research funding from: Novartis, BMS/Celgene, and CTI. FP received travel support from Syndax Pharmaceuticals and CHARM Therapeutics. RZ has received honoraria from Novartis, Incyte, Sanofi, and Mallinckrodt. HLP has no conflicts of interest to disclose.
